Welcome to the UPF Digital Repository

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.



Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

Thumbnail
Document Type: Article
Version: Published version
Date: 2016
This document is associated with a Creative Common license © 2016 Troya et al/nThis is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This item appears in the following Collection(s)

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking